Dr. Michael Notaras is a Vice President at Decheng Capital and has been with the firm since July of 2023.
Prior to joining Decheng Capital, Dr. Notaras was an Associate in the Biotechnology Equity Research team at Morgan Stanley, where he vetted healthcare deals while also covering 30+ therapeutic stocks with up to ~$30B in market capitalization. Prior to joining Morgan Stanley, Dr. Notaras was an Associate at Wolfe Research where he covered major large-cap biotechnology stocks and strategics with up to ~$120B in market capitalization.
Prior to his career in finance, Dr. Notaras was a NHMRC CJ Martin fellow at Weill Cornell Medical College of Cornell University where he discovered the first evidence of multiple schizophrenia mechanisms in patient-derived 3D tissue samples generated from human stem cells. In addition, Dr. Notaras also reported local mRNA degradation mechanisms in neuronal compartments, elucidating the role for nonsense-mediated decay in synaptic plasticity. Michael has published 25 scientific manuscripts (with 4 cover features), been the recipient of over half a million dollars in scholarships, fellowships, and other academic awards. Dr. Notaras holds a Ph.D. in Neuroscience from the University of Melbourne in Australia.